Concepedia

Publication | Open Access

<i>miR-26a</i> Limits Muscle Wasting and Cardiac Fibrosis through Exosome-Mediated microRNA Transfer in Chronic Kidney Disease

152

Citations

44

References

2019

Year

Abstract

Uremic cardiomyopathy and muscle atrophy are associated with insulin resistance and contribute to chronic kidney disease (CKD)-induced morbidity and mortality. We hypothesized that restoration of <i>miR-26a</i> levels would enhance exosome-mediated microRNA transfer to improve muscle wasting and cardiomyopathy that occur in CKD. <b>Methods:</b> Using next generation sequencing and qPCR, we found that CKD mice had a decreased level of <i>miR-26a</i> in heart and skeletal muscle. We engineered an exosome vector that contained <i>Lamp2b,</i> an exosomal membrane protein gene fused with a muscle-specific surface peptide that targets muscle delivery. We transfected this vector into muscle satellite cells and then transduced these cells with adenovirus that expresses <i>miR-26a</i> to produce exosomes encapsulated <i>miR-26a</i> (Exo/<i>miR-26a</i>). Exo/<i>miR-26a</i> was injected once per week for 8 weeks into the tibialis anterior (TA) muscle of 5/6 nephrectomized CKD mice. <b>Results:</b> Treatment with Exo/<i>miR-26a</i> resulted in increased expression of <i>miR-26a</i> in skeletal muscle and heart. Overexpression of <i>miR-26a</i> increased the skeletal muscle cross-sectional area, decreased the upregulation of FBXO32/atrogin-1 and TRIM63/MuRF1 and depressed cardiac fibrosis lesions. In the hearts of CKD mice, FoxO1 was activated, and connective tissue growth factor, fibronectin and collagen type I alpha 1 were increased. These responses were blunted by injection of Exo/<i>miR-26a</i>. Echocardiograms showed that cardiac function was improved in CKD mice treated with Exo/<i>miR-26a</i>. <b>Conclusion:</b> Overexpression of <i>miR-26a</i> in muscle prevented CKD-induced muscle wasting and attenuated cardiomyopathy via exosome-mediated <i>miR-26a</i> transfer. These results suggest possible therapeutic strategies for using exosome delivery of <i>miR-26a</i> to treat complications of CKD.

References

YearCitations

2009

1.5K

2005

1.2K

2014

1.1K

2014

708

2006

596

2005

574

2009

508

2005

453

2007

439

2002

376

Page 1